{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:19:51Z","timestamp":1782793191156,"version":"3.54.5"},"reference-count":33,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72374167"],"award-info":[{"award-number":["72374167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Objectives: The objective of this study is to quantify healthcare resource utilization, economic burden, and the multi-level medical security system for Spinal Muscular Atrophy (SMA) patients in Shaanxi Province, China, from a societal perspective using a survey. Methods: This observational study employed an online survey with a retrospective cross-sectional design in Shaanxi Province, China. The survey examined various aspects of SMA, including resource utilization, direct and indirect economic burdens, and co-payment mechanisms within a multi-level medical security system. Results: Following the inclusion of nusinersen in the National Reimbursement Drug List (NRDL) in 2022, the treatment rate for SMA patients increased significantly. After risdiplam was added to the NRDL in 2023, its use also saw a marked increase. Treatment costs varied by SMA type: Type 1 incurred the highest costs (RMB 300,000 or USD 41,000), followed by Type 2 (RMB 270,000 or USD 37,000), Type 3 (RMB 200,000 or USD 27,000), and Type 4 (RMB 80,000 or USD 11,000). The primary sources of costs were productivity losses due to primary caregivers (32.94%), nusinersen usage (29.29%), and risdiplam usage (17.33%). Out-of-pocket costs for SMA patients accounted for 29.29% of the total costs. In 2023, basic medical insurance covered 49% of direct costs and 32% of total costs. Patients still had to pay 25.73% of the total cost for the direct costs. Conclusions: Basic medical insurance is a critical foundation for patient security and plays a pivotal role in reimbursement. In contrast, commercial insurance has a relatively limited impact on covering the costs for SMA patients. These findings highlight the substantial healthcare burden faced by SMA patients under the current healthcare system in China.<\/jats:p>","DOI":"10.3390\/healthcare13040428","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T10:26:12Z","timestamp":1739787972000},"page":"428","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Healthcare Resource Utilization, Economic Burden, and Multi-Level Medical Security System for Individuals with Spinal Muscular Atrophy in Shaanxi Province, China"],"prefix":"10.3390","volume":"13","author":[{"given":"Mingyue","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0238-4699","authenticated-orcid":false,"given":"Chenglong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: From phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2147\/DDDT.S214174","article-title":"Disease modifying therapies for the management of children with spinal muscular atrophy (5q SMA): An update on the emerging evidence","volume":"16","author":"Hjartarson","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","unstructured":"(2024, November 26). European Medicines Agency: Summary of Product Characteristics: Spinraza 12 mg Solution for Injection. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spinraza-epar-product-information_en.pdf."},{"key":"ref_8","unstructured":"(2024, December 02). European Medicines Agency: Summary of Product Characteristics: Zolgensma 2 \u00d7 1013 Vector Genomes\/mL Solution for Infusion. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zolgensma-epar-product-information_en.pdf."},{"key":"ref_9","unstructured":"(2024, December 20). European Medicines Agency, Summary of Product Characteristics: Evrysdi. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kawalec, P., Tesar, T., Vostalova, L., Draganic, P., Manova, M., Savova, A., Petrova, G., Rugaja, Z., M\u00e4nnik, A., and Sowada, C. (2017). Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00892"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10198-010-0274-y","article-title":"Reimbursement of pharmaceuticals: Reference pricing versus health technology assessment","volume":"12","author":"Drummond","year":"2011","journal-title":"Eur. J. Health Econ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10198-017-0871-0","article-title":"Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight European countries","volume":"19","author":"Angelis","year":"2018","journal-title":"Eur. J. Health Econ."},{"key":"ref_13","first-page":"3","article-title":"International experience in the application of HTA to drug negotiation in China\u2019s medical insurance system","volume":"2020","author":"Han","year":"2020","journal-title":"China Med. Insur."},{"key":"ref_14","unstructured":"National Healthcare Security Administration, and Ministry of Human Resources and Social Security of the People\u2019s Republic of China (2024, October 25). Notice on the Issuance of the National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug Directory, Available online: https:\/\/www.nhsa.gov.cn\/art\/2023\/1\/18\/art_104_10078.html."},{"key":"ref_15","unstructured":"National Healthcare Security Administration, and Ministry of Human Resources and Social Security of the People\u2019s Republic of China (2024, October 25). Notice on the Issuance of the National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug Directory, Available online: https:\/\/www.gov.cn\/zhengce\/zhengceku\/2021-12\/03\/content_5655651.htm."},{"key":"ref_16","unstructured":"The State Council of the People\u2019s Republic of China (2024, October 25). Opinions on Deepening the Reform of the Medical Security System, Available online: https:\/\/www.gov.cn\/zhengce\/2020-03\/05\/content_5487407.htm."},{"key":"ref_17","unstructured":"National Healthcare Security Administration (2024, October 27). The National Healthcare Security Administration Attends the Press Conference on the Theme of \u201cPromoting High-Quality Development\u201d Series Hosted by the State Council Information Office, Available online: https:\/\/www.nhsa.gov.cn\/art\/2024\/9\/10\/art_14_13819.html."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","article-title":"Disease burden of spinal muscular atrophy in Germany","volume":"11","author":"Klug","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40273-021-01095-6","article-title":"Systematic literature review to assess economic evaluations in spinal muscular atrophy (SMA)","volume":"40","author":"Paracha","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"Dangoulof","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40273-021-01105-7","article-title":"Systematic literature review to assess the cost and resource use associated with spinal muscular atrophy management","volume":"40","author":"Paracha","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40258-020-00624-2","article-title":"Costs of illness of spinal muscular atrophy: A systematic review","volume":"19","author":"Landfeldt","year":"2021","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s10198-022-01548-5","article-title":"Significant healthcare burden and life cost of spinal muscular atrophy: Real-world data","volume":"24","author":"Chan","year":"2023","journal-title":"Eur. J. Health Econ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e57353","DOI":"10.2196\/57353","article-title":"Patterns of the Health and Economic Burden of 33 Rare Diseases in China: Nationwide Web-Based Study","volume":"10","author":"Yu","year":"2024","journal-title":"JMIR Public Health Surveill."},{"key":"ref_25","unstructured":"(2024, October 27). Meier Advocacy & Support Center for. \u201cBeijing Children\u2019s Spinal Muscular Atrophy Care Center\u201d. Available online: http:\/\/www.meier.org.cn\/."},{"key":"ref_26","unstructured":"Blue Cross Blue Shield (2024, October 27). Zolgensma (Onasemnogene Abeparvovec-Xioi) for Spinal Muscular Atrophy (SMA). Available online: https:\/\/www.bluecrossma.org\/medical-policies\/sites\/g\/files\/csphws2091\/files\/acquiadam-assets\/008%20Zolgensma%20%28onasemnogene%20abeparvovec-xioi%29%20for%20Spinal%20Muscular%20Atrophy%20prn.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/13696998.2016.1198355","article-title":"The economic burden of spinal muscular atrophy","volume":"19","author":"Armstrong","year":"2016","journal-title":"J. Med. Econ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","article-title":"Economic burden of spinal muscular atrophy in the United States: A contemporary assessment","volume":"23","author":"Droege","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JND-200610","article-title":"Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada","volume":"8","author":"McMillan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1007\/s12325-023-02621-y","article-title":"Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis","volume":"40","author":"Toro","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_31","unstructured":"The Lewin Group Inc. (2024, November 26). Cost of Amyotrophic Lateral Sclerosis, Muscular Dystrophy, and Spinal Muscular Atrophy in the United States: Final Report. Available online: https:\/\/www.mda.org\/sites\/default\/files\/Cost_Illness_Report_0.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12955-023-02204-z","article-title":"Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy","volume":"21","author":"Xu","year":"2023","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12955-024-02264-9","article-title":"Measurement properties of the EQ-5D-Y-3L, PedsQL 4.0, and PROMIS-25 Profile v2.0 in pediatric patients with spinal muscular atrophy","volume":"22","author":"Xu","year":"2024","journal-title":"Health Qual. Life Outcomes"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/13\/4\/428\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:35:48Z","timestamp":1760027748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/13\/4\/428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["healthcare13040428"],"URL":"https:\/\/doi.org\/10.3390\/healthcare13040428","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]}}}